C4 Therapeutics (NASDAQ: CCCC) is a clinical-stage biopharmaceutical company focused on targeted protein degradation as a therapeutic approach. The company does not generate product revenue. Its revenue model relies on collaboration agreements, milestones, and research funding from pharmaceutical partners rather than commercial drug sales. The available filing excerpts from the 10-K filed 2026-02-26 (accession 000162828026012000) do not contain sufficient detail to characterize specific programs, pipeline assets, partnership terms, financial results, leadership, founding year, headquarters, or competitive positioning. No specific revenue figures, customer concentrations, geographic breakdowns, or named competitors are supported by the excerpts provided. A complete business description requires access to the full filing body.

Revenue model

Collaboration agreements and research partnerships. No product revenue supported by the provided excerpts.

Products and services

Not supported by the provided filing excerpts.

Customers and end markets

Not supported by the provided filing excerpts.

Value-chain role

Clinical-stage drug developer focused on targeted protein degradation, based on company name and ticker context within the excerpts provided.

Geographic exposure

Not supported by the provided filing excerpts.

Source: SEC 10-K, filed 2026-02-26

Industry: Biological Products, (No Diagnostic Substances) Peers: ADMA Biologics Inc Aura Biosciences Inc Organogenesis Holdings Inc bluebird bio, Inc. Inovio Pharmaceuticals Inc Precigen Inc Lexicon Pharmaceuticals Inc Protagonist Therapeutics Inc Rallybio Corp